Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 359

1.

Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms.

DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, Rodriguez V, Gangat N, Wolanskyj A, Pruthi RK, Chen D, He R, Viswanatha DS, Lasho T, Finke C, Tefferi A, Pardanani A, Patnaik MM.

Leukemia. 2020 Feb 14. doi: 10.1038/s41375-020-0752-x. [Epub ahead of print] No abstract available.

PMID:
32060405
2.

Pregnancy outcomes in myeloproliferative neoplasms: A Mayo clinic report on 102 pregnancies.

Gangat N, Joshi M, Shah S, Yogarajah M, Patnaik MM, Pardanani A, Wolanskyj-Spinner AP, Tefferi A.

Am J Hematol. 2020 Feb 5. doi: 10.1002/ajh.25748. [Epub ahead of print] No abstract available.

PMID:
32020655
3.

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.

Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM.

Br J Haematol. 2020 Jan 16. doi: 10.1111/bjh.16380. [Epub ahead of print]

PMID:
31945802
4.

Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.

Coltro G, Antelo G, Lasho TL, Finke CM, Pardanani A, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Fernandez-Zapico ME, Robertson KD, Bosi A, Vannucchi AM, Tefferi A, Patnaik MM.

Am J Hematol. 2020 Jan 10. doi: 10.1002/ajh.25721. [Epub ahead of print] No abstract available.

PMID:
31925810
5.

Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia.

Anagnostou T, Knudson RA, Pearce KE, Meyer RG, Pitel BA, Peterson JF, Baughn LB, Reichard KK, Ketterling RP, Kloft-Nelson SM, Knutson DL, Khan SP, Gangat N, Litzow MR, Hogan WJ, Wolanskyj A, Al-Kali A, Begna KH, Elliott M, Pardanani A, Foran J, Shah M, Tefferi A, Alkhateeb H, Halling K, Rodriguez V, Greipp PT, Patnaik MM.

Am J Hematol. 2020 Mar;95(3):E68-E72. doi: 10.1002/ajh.25729. Epub 2020 Jan 26. No abstract available.

PMID:
31919873
6.

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.

Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM.

Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0690-7. [Epub ahead of print]

PMID:
31836856
7.

Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with Hypereosinophilia: A reference laboratory experience.

Shi M, Rech KL, Otteson GE, Horna P, Olteanu H, Pardanani A, Chen D, Jevremovic D.

Ann Diagn Pathol. 2020 Feb;44:151412. doi: 10.1016/j.anndiagpath.2019.151412. Epub 2019 Oct 18.

PMID:
31778950
8.

Essential Thrombocythemia.

Tefferi A, Pardanani A.

N Engl J Med. 2019 Nov 28;381(22):2135-2144. doi: 10.1056/NEJMcp1816082. Review. No abstract available.

PMID:
31774958
9.

Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.

Tischer A, Antelo G, Coltro G, Finke CM, Gonsalves W, Pardanani A, Ketterling R, Mangaonkar A, Gangat N, Tefferi A, Patnaik MM, Lasho TL.

Leuk Res. 2019 Dec;87:106264. doi: 10.1016/j.leukres.2019.106264. Epub 2019 Oct 24. No abstract available.

PMID:
31706195
10.

Etiologies of Extreme Thrombocytosis: A Contemporary Series.

Hsieh RW, Ravindran A, Hook CC, Begna KH, Ashrani AA, Pruthi RK, Marshall AL, Hogan W, Litzow M, Hoyer J, Oliveira JL, Vishnu P, Call TG, Al-Kali A, Patnaik M, Gangat N, Pardanani A, Tefferi A, Go RS.

Mayo Clin Proc. 2019 Aug;94(8):1542-1550. doi: 10.1016/j.mayocp.2019.01.041.

PMID:
31378229
11.

Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study.

Haddox CL, Carr RM, Abraham RS, Perez Botero J, Rodriguez V, Pardanani A, Patnaik MM.

Leuk Lymphoma. 2019 Dec;60(13):3282-3286. doi: 10.1080/10428194.2019.1633630. Epub 2019 Jun 27. No abstract available.

PMID:
31246134
12.

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, Jevremovic D, Altman JK, Patnaik MM.

Am J Hematol. 2019 Jun 7. doi: 10.1002/ajh.25552. [Epub ahead of print] No abstract available.

PMID:
31173385
13.

Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies.

Tefferi A, Nicolosi M, Penna D, Vallapureddy R, Hanson CA, Pardanani A, Gangat N, Ketterling RP.

Leukemia. 2019 Oct;33(10):2522-2553. doi: 10.1038/s41375-019-0453-5. Epub 2019 May 1. No abstract available.

PMID:
31040370
14.

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM.

Am J Hematol. 2019 Jul;94(7):767-779. doi: 10.1002/ajh.25488. Epub 2019 May 3.

PMID:
30964202
15.

World Health Organization class-independent risk categorization in mastocytosis.

Pardanani A, Lasho TL, Reichard KK, Hanson CA, Tefferi A.

Blood Cancer J. 2019 Mar 4;9(3):29. doi: 10.1038/s41408-019-0189-5. No abstract available.

16.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
17.

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 25;9(2):12. doi: 10.1038/s41408-019-0175-y.

18.

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Gangat N, Phelps A, Lasho TL, Finke CM, Vallapureddy R, Hanson CA, Ketterling RP, Patnaik MM, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 24;9(2):11. doi: 10.1038/s41408-018-0167-3. No abstract available.

19.

Calculator-free point-of-care prognostication in myelodysplastic syndromes.

Tefferi A, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Apr;94(4):E99-E101. doi: 10.1002/ajh.25400. Epub 2019 Jan 24. No abstract available.

PMID:
30637785
20.

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A.

Haematologica. 2019 Jun;104(6):e236-e239. doi: 10.3324/haematol.2018.208082. Epub 2019 Jan 3. No abstract available.

21.

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2018 Dec;16(12):1500-1537. doi: 10.6004/jnccn.2018.0088.

PMID:
30545997
22.

Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.

Pardanani A.

Am J Hematol. 2019 Mar;94(3):363-377. doi: 10.1002/ajh.25371. Epub 2019 Jan 2. Review.

PMID:
30536695
23.

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.

Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2019 Mar;94(3):286-290. doi: 10.1002/ajh.25351. Epub 2018 Dec 5.

PMID:
30516867
24.

The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.

Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Am J Hematol. 2019 Mar;94(3):299-305. doi: 10.1002/ajh.25349. Epub 2018 Dec 5.

PMID:
30516848
25.

MPL-mutated essential thrombocythemia: a morphologic reappraisal.

Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3. No abstract available.

26.

Genetic predictors of response to specific drugs in primary myelofibrosis.

Penna D, Szuber N, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):120. doi: 10.1038/s41408-018-0158-4. No abstract available.

27.

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.

Szuber N, Lavu S, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):118. doi: 10.1038/s41408-018-0157-5. No abstract available.

28.

Mutations and prognosis in myeloproliferative neoplasms.

Tefferi A, Pardanani A.

Leuk Lymphoma. 2019 May;60(5):1112-1113. doi: 10.1080/10428194.2018.1537490. Epub 2018 Nov 14. No abstract available.

PMID:
30424706
29.

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A.

Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.

30.

Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis.

Szuber N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Leukemia. 2019 Mar;33(3):780-785. doi: 10.1038/s41375-018-0283-x. Epub 2018 Oct 12. No abstract available.

PMID:
30315236
31.

Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis.

Tefferi A, Shah S, Reichard KK, Hanson CA, Pardanani A.

Am J Hematol. 2019 Jan;94(1):E1-E2. doi: 10.1002/ajh.25302. Epub 2018 Nov 9. No abstract available.

32.

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.

Tefferi A, Szuber N, Vallapureddy RR, Begna KH, Patnaik MM, Elliott MA, Christopher Hook C, Wolanskyj AP, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Jan;94(1):5-9. doi: 10.1002/ajh.25294. Epub 2018 Oct 17.

33.

A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.

Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):E401-E404. doi: 10.1002/ajh.25290. Epub 2018 Oct 17. No abstract available.

34.

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.

Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, Pardanani A, Droin N, Gangat N, Tefferi A, Solary E.

Blood Cancer J. 2018 Aug 22;8(9):82. doi: 10.1038/s41408-018-0120-5. No abstract available.

35.

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.

Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1474-1484. doi: 10.1002/ajh.25270. Epub 2018 Sep 27.

36.

Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm.

Tefferi A, Shah S, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Pardanani A.

Am J Hematol. 2018 Dec;93(12):E383-E386. doi: 10.1002/ajh.25269. Epub 2018 Oct 17. No abstract available.

37.

Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.

Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G.

Hematol Oncol. 2019 Feb;37(1):96-102. doi: 10.1002/hon.2557. Epub 2018 Dec 5.

38.

Mutations and karyotype predict treatment response in myelodysplastic syndromes.

Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Nov;93(11):1420-1426. doi: 10.1002/ajh.25267. Epub 2018 Sep 30.

39.

Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases.

Shah S, Pardanani A, Elala YC, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1461-1466. doi: 10.1002/ajh.25265. Epub 2018 Sep 26.

40.

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels.

Tefferi A, Nicolosi M, Penna D, Mudireddy M, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani AD.

Blood Adv. 2018 Aug 14;2(15):1980-1984. doi: 10.1182/bloodadvances.2018018051. No abstract available.

41.

Myelofibrosis Treatment Algorithm 2018.

Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Blood Cancer J. 2018 Jul 31;8(8):72. doi: 10.1038/s41408-018-0109-0. Review.

42.

A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience.

Fang H, Ketterling RP, Hanson CA, Pardanani A, Kurtin PJ, Chen D, Greipp PT, Howard MT, King RL, Van Dyke DL, Reichard KK.

Am J Clin Pathol. 2018 Oct 1;150(5):421-431. doi: 10.1093/ajcp/aqy064.

PMID:
30032299
43.

Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis.

Mudireddy M, Gangat N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Ashrani AA, Pardanani A, Nagorney DM, Tefferi A.

Am J Hematol. 2018 Sep;93(9):E235-E238. doi: 10.1002/ajh.25203. Epub 2018 Aug 31. No abstract available.

44.

Mast cell activation syndrome: Importance of consensus criteria and call for research.

Valent P, Akin C, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Reiter A, Gotlib J, Castells M, Milner JD, Carter MC, Komarow H, Radia D, Pardanani A, Sotlar K, Triggiani M, Horny HP, Arock M, Schwartz LB, Metcalfe DD.

J Allergy Clin Immunol. 2018 Sep;142(3):1008-1010. doi: 10.1016/j.jaci.2018.06.004. Epub 2018 Jun 19. No abstract available.

PMID:
29928922
45.

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis.

Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.

Blood Cancer J. 2018 Jun 11;8(6):57. doi: 10.1038/s41408-018-0095-2. No abstract available.

46.

How I treat myelofibrosis after failure of JAK inhibitors.

Pardanani A, Tefferi A.

Blood. 2018 Aug 2;132(5):492-500. doi: 10.1182/blood-2018-02-785923. Epub 2018 Jun 4.

PMID:
29866811
47.

Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA.

Mayo Clin Proc. 2018 Oct;93(10):1363-1374. doi: 10.1016/j.mayocp.2018.04.013. Epub 2018 Jun 14.

PMID:
29866419
48.

Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience.

Oliveira JL, Coon LM, Frederick LA, Hein M, Swanson KC, Savedra ME, Porter TR, Patnaik MM, Tefferi A, Pardanani A, Grebe SK, Viswanatha DS, Hoyer JD.

Am J Hematol. 2018 May 23. doi: 10.1002/ajh.25150. [Epub ahead of print]

49.

A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.

Patnaik MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, Hanson CA, Gangat N, Tefferi A, Pardanani A.

Leukemia. 2018 Aug;32(8):1850-1856. doi: 10.1038/s41375-018-0121-1. Epub 2018 Apr 2. No abstract available.

PMID:
29712989
50.

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM.

J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30. No abstract available.

PMID:
29708808

Supplemental Content

Loading ...
Support Center